Moderna CEO Stéphane Bancel’s comments — made during The Wall Street Journal’s annual Tech Live conference yesterday and reported in the newspaper — suggest that the Cambridge, Mass.-based biotech company is on a similar timetable to Pfizer (NYSE:PFE). Pfizer is planning an EUA application for its COVID-19 vaccine in late November.
Bancel cautioned that Moderna may not secure an EUA until early next year if it takes longer to collect sufficient interim results.
Moderna’s COVID-19 vaccine candidate is among a handful that are presently in Phase 3 clinical trials in the U.S.
Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease